Logo

Samsung Bioepis Reports Results of SB11 (proposed biosimilar ranibizumab) in P-III Study for Neovascular Age-Related Macular Degeneration

Share this

Samsung Bioepis Reports Results of SB11 (proposed biosimilar ranibizumab) in P-III Study for Neovascular Age-Related Macular Degeneration

Shots:

  •  The P-III study involves assessing of SB11 vs reference product- LUCENTIS in monthly injections (0.5mg) in 705 patients in a ratio (1:1) with nAMD
  • The P-III study results demonstrated equivalent efficacy in terms of change in BCVA @8wk. and CST @4wk.- LS change in BCVA (6.2 vs 7.0 letters)- LS change in CST ( −108.4μm vs −100.1μm)- AEs (66.0% vs 66.9%). The data was to be presented at ARVO 2020 which has been cancelled due to COVID-19
  • Additionally- in Nov’2019- Samsung collaborated with Biogen for two ophthalmology biosimilar candidates- SB11 (ranibizumab) and SB15 (aflibercept)- in the US- Canada- EU- Japan- and Australia

Click here to read full press release/ article | Ref: Samsung Bioepis | Image: Samsung Bioepis

Related News: Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions